ClinicalTrials.Veeva

Menu

Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

Intra-Cellular Therapies logo

Intra-Cellular Therapies

Status and phase

Enrolling
Phase 1

Conditions

Autism Spectrum Disorder

Treatments

Drug: Lumateperone 5 mg ODT
Drug: Lumateperone 10.5 mg capsule
Drug: Lumateperone 21 mg ODT
Drug: Lumateperone 10.5 mg ODT
Drug: Lumateperone 15.5 mg ODT
Drug: Lumateperone 21 mg capsule

Study type

Interventional

Funder types

Industry

Identifiers

NCT06557902
ITI-007-035

Details and patient eligibility

About

Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.

Enrollment

26 estimated patients

Sex

All

Ages

5 to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female patients between 5 to less than 13 years of age
  • Primary clinical diagnosis of ASD with symptoms of irritability
  • ABC-I subscale score of ≥12 at Screening
  • CGI-S score of ≥3 at Screening
  • Body mass index (BMI) greater than the 5th percentile according to age- and gender-specific CDC Clinical Growth Charts (2000) at Screening
  • Ability to swallow capsules

Exclusion criteria

  • Has a primary psychiatric diagnosis other than ASD
  • Reports suicidal ideation (Type 3, 4 or 5 on the Baseline/Screening version of the C-SSRS) within 6 months prior to Screening, or any suicidal behavior within 2 years prior to Screening, and/or the Investigator assesses the patient to be a safety risk to him/herself or others
  • Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables
  • History of a clinically significant cardiac disorder and/or abnormal screening ECG or a QT interval corrected for heart rate using Fridericia formula (QTcF) > 460 msec at Screening
  • Patients with a history of orthostatic hypotension or who have orthostatic hypotension at Screening
  • Has a history of uncontrolled/disruptive behavior in the past 30 days that, in the Investigator's opinion, would preclude the ability to participate in study procedures

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

26 participants in 2 patient groups

Group 1 (10 to less than 13 years)
Experimental group
Description:
Lumateperone capsule once daily: 10.5 mg on Days 1 and 2; 10.5 mg or 21 mg on Day 3; 10.5 mg or 21 mg on Days 4 and 5
Treatment:
Drug: Lumateperone 21 mg capsule
Drug: Lumateperone 10.5 mg capsule
Group 2 (5 to less than 10 years)
Experimental group
Description:
Lumateperone ODT once daily: 5 mg on Days 1 and 2; 5 mg or 10.5 mg on Day 3; 5 mg or 10.5 mg on Days 4 and 5; dosing regimen may be adjusted after the first 6 patients dosed and will not exceed 21 mg in subsequent patients
Treatment:
Drug: Lumateperone 15.5 mg ODT
Drug: Lumateperone 10.5 mg ODT
Drug: Lumateperone 21 mg ODT
Drug: Lumateperone 5 mg ODT

Trial contacts and locations

8

Loading...

Central trial contact

ITI Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems